The Duke Human Vaccine Institute (DHVI) has established a place of national and international leadership in the fight against major infectious diseases. DHVI plays an integral leadership role in the Global HIV/AIDS Vaccine Enterprise and is a pioneer in emerging infections and biodefense research. By focusing on the scientific “bottlenecks” for the development of HIV, TB, and other vaccines, DHVI investigators continue to make significant contributions to overcome global health challenges on behalf of society. More

Press Releases

Scanning electron micrograph of HIV particles infecting a human H9 T cell, colorized in blue, turqoise, and yellow. Credit: NIAID

Recent Publications

Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission.
Permar SR, Fong Y, Vandergrift N, Fouda GG, Gilbert P, Parks R, Jaeger FH, Pollara J, Martelli A, Liebl BE, Lloyd K, Yates NL, Overman RG, Shen X, Whitaker K, Chen H, Pritchett J, Solomon E, Friberg E, Marshall DJ, Whitesides JF, Gurley TC, Von Holle T, Martinez DR, Cai F, Kumar A, Xia SM, Lu X, Louzao R, Wilkes S, Datta S, Sarzotti-Kelsoe M, Liao HX, Ferrari G, Alam SM, Montefiori DC, Denny TN, Moody MA, Tomaras GD, Gao F, Haynes BF. J Clin Invest. 2015 Jun 8. pii: 81593. doi: 10.1172/JCI81593.

New approaches to HIV vaccine development.
Haynes BF. Curr Opin Immunol. 2015 Jun 4;35:39-47. doi: 10.1016/j.coi.2015.05.007. Review. PMID: 26056742

Kernel-based logistic regression model for protein sequence without vectorialization.
Fong Y, Datta S, Georgiev IS, Kwong PD, Tomaras GD. Biostatistics. 2014 Dec 22. pii: kxu056. [Epub ahead of print]

Video Presentations

Broadly neutralizing HIV-1 antibody identified in a lupus patient
March 11, 2014
Dr. Barton Haynes, DHVI and Duke CHAVI-ID Director, discusses recent findings from a study led by DHVI investigators in which a broadly neutralizing antibody was identified in a lupus patient who was chronically infected with HIV.